- Home
- EAD vs CTNM Comparison
EAD vs CTNM Comparison
Compare EAD & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAD
- CTNM
- Stock Information
- Founded
- EAD 2003
- CTNM 2009
- Country
- EAD United States
- CTNM United States
- Employees
- EAD N/A
- CTNM N/A
- Industry
- EAD Finance/Investors Services
- CTNM
- Sector
- EAD Finance
- CTNM
- Exchange
- EAD Nasdaq
- CTNM Nasdaq
- Market Cap
- EAD 404.8M
- CTNM 328.1M
- IPO Year
- EAD N/A
- CTNM 2024
- Fundamental
- Price
- EAD $6.91
- CTNM $10.97
- Analyst Decision
- EAD
- CTNM Strong Buy
- Analyst Count
- EAD 0
- CTNM 5
- Target Price
- EAD N/A
- CTNM $22.20
- AVG Volume (30 Days)
- EAD 178.9K
- CTNM 100.4K
- Earning Date
- EAD 01-01-0001
- CTNM 11-06-2025
- Dividend Yield
- EAD 8.91%
- CTNM N/A
- EPS Growth
- EAD N/A
- CTNM N/A
- EPS
- EAD N/A
- CTNM N/A
- Revenue
- EAD N/A
- CTNM N/A
- Revenue This Year
- EAD N/A
- CTNM N/A
- Revenue Next Year
- EAD N/A
- CTNM N/A
- P/E Ratio
- EAD N/A
- CTNM N/A
- Revenue Growth
- EAD N/A
- CTNM N/A
- 52 Week Low
- EAD $5.69
- CTNM $3.35
- 52 Week High
- EAD $6.81
- CTNM $20.24
- Technical
- Relative Strength Index (RSI)
- EAD 46.76
- CTNM 47.41
- Support Level
- EAD $6.74
- CTNM $10.16
- Resistance Level
- EAD $6.92
- CTNM $11.34
- Average True Range (ATR)
- EAD 0.06
- CTNM 0.79
- MACD
- EAD 0.00
- CTNM -0.20
- Stochastic Oscillator
- EAD 51.56
- CTNM 28.97
About EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.